Previous 10 | Next 10 |
All 8 patients treated with OTX-2002 in initial two cohorts achieved highly specific on-target genomic engagement, intended epigenetic state change and robust downregulation in expression of c-MYC , a historically ‘undruggable’ target First-known clinical observation of ...
2023-09-26 05:30:10 ET Stock futures edged down in the early hours of Tuesday, ahead of important economic data releases later in the day. Here are some of Tuesday's biggest stock movers in premarket trading: Biggest stock gainers Pliant Therapeutics ( NASDAQ: PLRX ) ...
2023-09-25 17:15:50 ET Gainers: Pliant Therapeutics ( NASDAQ: PLRX ) +8% . ARS Pharmaceuticals ( SPRY ) +6% . Amylyx Pharmaceuticals ( AMLX ) +4% . Seres Therapeutics ( MCRB ) +2% . Pulmonx Corporation ( LUNG ) +2% . Lo...
CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will host a conference ...
2023-09-20 10:00:02 ET More on Health Care Select Sector SPDR Health Care Select Sector SPDR ETF declares quarterly distribution of $0.5395 BofA clients were net buyers of U.S. equities for a fifth consecutive week Wolfe Research stays defensive as it says markets wi...
Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer PR Newswire CAMBRIDGE, Mass. , Sept. 11, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda K...
Chris Schade to Assume Role of Chairman of the Board, Succeeding Noubar Afeyan, Ph.D. Michelle C. Werner, CEO of Alltrna, Appointed to Board of Directors CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical...
2023-08-10 17:57:14 ET Gainers: Eton Pharmaceuticals ( ETON ) +23% . EBIX ( EBIX ) +3% . Innodata ( INOD ) +12% . Consolidated Water ( CWCO ) +8% . Omega Therapeutics ( OMGA ) +5% . Losers: Biote ( BTMD ) ...
2023-08-03 17:29:51 ET Omega Therapeutics press release ( NASDAQ: OMGA ): Q2 GAAP EPS of -$0.54 misses by $0.04 . Revenue of $0.76M (+58.3% Y/Y) beats by $0.33M . For further details see: Omega Therapeutics GAAP EPS of -$0.54 misses by $0.04, revenue of $...
Continued Enrollment in Monotherapy Dose Escalation Stage of Phase 1/2 MYCHELANGELO™ I Study; Preliminary First-in-Human Safety, Tolerability, Pharmacologic and Translational Data Anticipated in the Fourth Quarter of 2023 Presented New Preclinical Data at the American Society of Cl...
News, Short Squeeze, Breakout and More Instantly...
Omega Therapeutics Inc. Company Name:
OMGA Stock Symbol:
NASDAQ Market:
Omega Therapeutics Inc. Website:
CAMBRIDGE, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the election of Richard N. Kender to its...
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will participate in fires...
CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the appointment of Kaan Certel, Ph.D., as...